Fowl Cholera in Poultry: Etiology, Clinical Presentation, and Management
By Dr. Zubair Khalid, DVM, MS, PhD ·

Key Takeaways
- Fowl cholera is caused by the Gram-negative bacterium Pasteurella multocida, primarily serogroup A in poultry, which can manifest in peracute, acute, and chronic forms with significant mortality.
- Transmission occurs horizontally via respiratory aerosols, contaminated feed/water, and fomites, with stressors like overcrowding precipitating clinical disease in asymptomatic carriers.
- Diagnosis relies on bacterial isolation and identification, confirmed by species-specific PCR targeting the kmt1 gene or LAMP assays, with whole-genome sequencing providing advanced strain typing.
- Antimicrobial therapy should be guided by antibiogram profiling, as multidrug resistance to tetracyclines, sulfonamides, and beta-lactams is prevalent; common treatments include oxytetracycline, florfenicol, and enrofloxacin.
- Integrated management strategies include strict biosecurity, vaccination with inactivated bacterins or live attenuated vaccines, and consideration of probiotics or phytotherapeutics to mitigate disease impact.
- Gross pathological findings in acute cases include generalized congestion, petechial hemorrhages, hepatomegaly with necrotic foci, and splenomegaly, while chronic forms present with localized abscesses.
Introduction
Fowl cholera, also known as avian pasteurellosis, is a highly contagious bacterial disease of domestic poultry and wild birds caused by infection with Pasteurella multocida [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>]. The disease manifests in peracute, acute, and chronic forms and is associated with significant morbidity, mortality, and economic losses in commercial chicken, turkey, and duck flocks worldwide [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>, <a href="#ref-5">5</a>]. The term "fowl cholera meaning in Bengali" is recognized in regional veterinary contexts as "পোল্ট্রি কলেরা," reflecting the disease's global distribution. This article provides a comprehensive review of the etiology, clinical presentation, diagnostic approaches, and management strategies for fowl cholera in poultry, with a focus on recent molecular and epidemiological findings.
Etiology
Fowl cholera is caused by Pasteurella multocida, a Gram-negative, facultatively anaerobic, nonmotile, bipolar-staining coccobacillus belonging to the family Pasteurellaceae [<a href="#ref-6">6</a>, <a href="#ref-7">7</a>]. The bacterium is classified into serogroups (A, B, D, E, F) based on capsular antigens and into 16 somatic serotypes (1 through 16) based on lipopolysaccharide (LPS) antigens [<a href="#ref-8">8</a>, <a href="#ref-9">9</a>]. Avian isolates belong predominantly to serogroup A, with serotypes 1, 3, and 4 being most frequently reported in poultry outbreaks [<a href="#ref-4">4</a>, <a href="#ref-5">5</a>, <a href="#ref-7">7</a>]. The question "fowl cholera is caused by which bacteria" is answered definitively: Pasteurella multocida.
The P. multocida genome encodes a variety of virulence factors. The polysaccharide capsule, composed of hyaluronic acid in serogroup A strains, is a critical antiphagocytic determinant [<a href="#ref-10">10</a>, <a href="#ref-11">11</a>]. The LPS outer core is essential for serum resistance and full virulence [<a href="#ref-12">12</a>, <a href="#ref-13">13</a>]. Filamentous hemagglutinins, such as FhaB1, mediate adherence to host epithelial cells [<a href="#ref-14">14</a>]. Pasteurella multocida toxin (PMT), encoded by the toxA gene, is a potent mitogen that activates intracellular signaling pathways, leading to cellular proliferation and immunosuppression [<a href="#ref-6">6</a>]. The stringent response, regulated by (p)ppGpp, negatively controls capsule production and influences metabolic adaptation within the host [<a href="#ref-11">11</a>].
Epidemiology and Transmission
P. multocida is carried asymptomatically in the nasopharynx and oropharynx of healthy birds, which act as reservoirs for transmission [<a href="#ref-15">15</a>, <a href="#ref-16">16</a>]. Stressors such as overcrowding, poor ventilation, nutritional deficiencies, and concurrent infections precipitate clinical disease [<a href="#ref-1">1</a>, <a href="#ref-17">17</a>]. Transmission occurs horizontally via respiratory aerosols, contaminated feed and water, and fomites. Vertical transmission is not considered a significant route [<a href="#ref-2">2</a>].
Outbreaks are frequently reported in commercial layers, broilers, turkeys, and ducks [<a href="#ref-3">3</a>, <a href="#ref-5">5</a>, <a href="#ref-17">17</a>]. A recent study documented 100% mortality in slow-growing broilers during an acute fowl cholera outbreak [<a href="#ref-1">1</a>]. In Morocco, serogroup A isolates were characterized from an outbreak in turkeys with high mortality [<a href="#ref-4">4</a>]. Coinfection with Mycoplasmoides gallisepticum exacerbates disease severity, resulting in elevated mortality in turkey flocks [<a href="#ref-17">17</a>]. Land cover and environmental factors, including proximity to water bodies, have been associated with increased fowl cholera occurrence [<a href="#ref-15">15</a>]. Sequence type 20 (ST20) is widespread in Australian poultry farms and may spill over into wild waterbird populations [<a href="#ref-16">16</a>].
The question of "avain cholera transmission to humans" is addressed by noting that P. multocida is a zoonotic pathogen capable of causing local wound infections and respiratory disease in humans following direct contact with infected birds or contaminated materials. However, human infections are rare and typically associated with immunocompromised individuals. This article focuses strictly on avian disease.
Clinical Presentation
The clinical presentation of fowl cholera depends on the disease course: peracute, acute, or chronic.
Peracute Form. Birds are found dead without premonitory signs [<a href="#ref-1">1</a>, <a href="#ref-18">18</a>]. Mortality can reach 100% in naive flocks within 24 to 48 hours [<a href="#ref-1">1</a>].
Acute Form. The acute form is the most common manifestation in chickens and turkeys [<a href="#ref-2">2</a>, <a href="#ref-19">19</a>]. Clinical signs include fever, depression, anorexia, ruffled feathers, cyanosis of the comb and wattles, increased respiratory rate, oral mucus discharge, and diarrhea [<a href="#ref-18">18</a>, <a href="#ref-19">19</a>]. Morbidity and mortality range from 20% to 80% depending on flock immunity and management [<a href="#ref-1">1</a>, <a href="#ref-4">4</a>].
Chronic Form. Chronic fowl cholera is characterized by localized infections including swollen wattles, facial edema, conjunctivitis, purulent sinusitis, torticollis from otitis media, and joint abscesses [<a href="#ref-20">20</a>, <a href="#ref-21">21</a>].
Differential diagnoses include avian influenza, infectious coryza, and necrotic enteritis. The condition "avian coryn" (as referenced in search terms) likely conflates avian coryza (caused by Avibacterium paragallinarum) with fowl cholera; differentiation is critical and is achieved through bacterial culture and molecular testing.
Pathology
Gross lesions in acute fowl cholera include generalized congestion, petechial hemorrhages on the epicardium and serosal surfaces, hepatomegaly with multiple pale necrotic foci, splenomegaly, and diffuse pneumonia [<a href="#ref-1">1</a>, <a href="#ref-18">18</a>, <a href="#ref-19">19</a>]. Chronic cases present with caseous abscesses in the wattles, joints, and infraorbital sinuses [<a href="#ref-20">20</a>, <a href="#ref-21">21</a>].
Histopathological examination reveals fibrinous necrosis in the liver, heterophilic infiltration, and vascular thrombosis [<a href="#ref-1">1</a>]. Capsular serogroup A strains induce more severe systemic lesions due to their antiphagocytic capsule [<a href="#ref-10">10</a>, <a href="#ref-11">11</a>].
Table 1. Representative Gross Pathology Findings in Acute Fowl Cholera
| Organ System | Lesion Description |
|---|---|
| Liver | Enlarged, friable, with multifocal 1-2 mm pale necrotic foci |
| Spleen | Marked splenomegaly, mottled |
| Heart | Petechial and ecchymotic hemorrhages on epicardium |
| Lungs | Congestion, edema, fibrinonecrotic pneumonia |
| Subcutis | Edema of wattles and cervical region (chronic cases) |
Pathogenesis
Following inhalation or ingestion, P. multocida adheres to the pharyngeal and respiratory epithelium through filamentous hemagglutinins and other adhesins [<a href="#ref-10">10</a>, <a href="#ref-14">14</a>]. The hyaluronic acid capsule inhibits phagocytosis and complement-mediated opsonization [<a href="#ref-11">11</a>]. The bacterium then invades the bloodstream, causing septicemia [<a href="#ref-6">6</a>]. PMT activates G-proteins in host cells, leading to cytoskeletal rearrangement and altered cytokine expression [<a href="#ref-6">6</a>]. The stringent response, involving the alarmone (p)ppGpp, downregulates capsule production during nutrient stress, modulating persistence in the host [<a href="#ref-11">11</a>]. LPS outer core composition influences serum resistance, with specific transferase genes (pcgD, hptE) contributing differently to virulence in ducks [<a href="#ref-12">12</a>, <a href="#ref-13">13</a>]. The hyaD gene product, involved in hyaluronic acid synthesis, is essential for full virulence [<a href="#ref-10">10</a>].
Diagnostics
Clinical and Necropsy Examination
Presumptive diagnosis is based on history, clinical signs, and characteristic gross lesions [<a href="#ref-1">1</a>, <a href="#ref-18">18</a>, <a href="#ref-19">19</a>].
Bacterial Isolation and Identification
Definitive diagnosis requires isolation of P. multocida from liver, spleen, heart blood, or bone marrow on blood agar or MacConkey agar [<a href="#ref-18">18</a>, <a href="#ref-19">19</a>]. Colonies appear as small, gray, mucoid, nonhemolytic after 24-48 hours of incubation at 37°C. Biochemical characterization includes oxidase and catalase positivity, indole production, and fermentation of glucose and sucrose but not lactose [<a href="#ref-19">19</a>, <a href="#ref-20">20</a>]. Bipolar staining with methylene blue is a classic cytological feature.
Molecular Diagnostics
Polymerase chain reaction (PCR) targeting the kmt1 gene (species-specific) and capsular typing genes provides rapid confirmation and serogroup identification [<a href="#ref-20">20</a>, <a href="#ref-22">22</a>]. Loop-mediated isothermal amplification (LAMP) assays offer a field-deployable alternative with comparable sensitivity and specificity to PCR [<a href="#ref-22">22</a>]. Genomic profiling through whole-genome sequencing enables high-resolution strain typing, virulence gene detection, and antimicrobial resistance gene identification [<a href="#ref-3">3</a>, <a href="#ref-8">8</a>, <a href="#ref-23">23</a>]. The kmt1 sequence analysis can reveal intraspecies diversity and predict pathogenic potential [<a href="#ref-20">20</a>].
Serological Methods
Enzyme-linked immunosorbent assays (ELISAs) using in-house protocols can detect antibodies against P. multocida in chicken sera, supporting serosurveillance and vaccine response monitoring [<a href="#ref-24">24</a>]. Subunit ELISA platforms using recombinant lipoprotein E (PlpE) show promise for standardized antibody detection [<a href="#ref-25">25</a>, <a href="#ref-26">26</a>].
Table 2. Summary of Diagnostic Methods for Fowl Cholera
| Method | Target | Sensitivity | Specificity | Reference |
|---|---|---|---|---|
| Bacterial culture | Viable P. multocida | Moderate | High | [<a href="#ref-18">18</a>, <a href="#ref-19">19</a>] |
| kmt1 PCR | Species-specific gene | High | High | [<a href="#ref-20">20</a>, <a href="#ref-22">22</a>] |
| LAMP assay | kmt1 or other gene | High | High | [<a href="#ref-22">22</a>] |
| Whole-genome sequencing | Genome | Highest | Highest | [<a href="#ref-3">3</a>, <a href="#ref-8">8</a>, <a href="#ref-23">23</a>] |
| Indirect ELISA | Antibodies | Moderate | Moderate | [<a href="#ref-24">24</a>, <a href="#ref-25">25</a>] |
Antibiogram Profiling
Antimicrobial susceptibility testing using disk diffusion or broth microdilution is essential for guiding therapy [<a href="#ref-18">18</a>, <a href="#ref-19">19</a>]. Multidrug resistance (MDR) is prevalent among avian P. multocida strains globally. MDR phenotypes frequently include resistance to tetracyclines, sulfonamides, aminoglycosides, and beta-lactams [<a href="#ref-19">19</a>, <a href="#ref-20">20</a>, <a href="#ref-23">23</a>, <a href="#ref-27">27</a>]. Resistance genes such as tet(B), *bla*ROB-1, and strA-strB are commonly identified via genomic sequencing [<a href="#ref-20">20</a>, <a href="#ref-23">23</a>].
Management
Antimicrobial Therapy
Antimicrobial treatment should be based on culture and sensitivity results. Oxytetracycline, florfenicol, enrofloxacin, and sulfadimethoxine-trimethoprim combinations are commonly used [<a href="#ref-2">2</a>, <a href="#ref-18">18</a>, <a href="#ref-19">19</a>]. The emergence of MDR strains limits therapeutic options [<a href="#ref-23">23</a>, <a href="#ref-27">27</a>]. Phytotherapeutic alternatives, such as wild Egyptian artichoke extract, have demonstrated in vitro antibacterial activity against P. multocida [<a href="#ref-28">28</a>]. Probiotic supplementation with multi-strain probiotics has been shown to reduce fowl cholera mortality in broilers, likely through competitive exclusion and immunomodulation [<a href="#ref-29">29</a>].
Vaccination
Vaccination is a cornerstone of fowl cholera prevention. Inactivated bacterins provide serogroup-specific protection but limited cross-protection [<a href="#ref-30">30</a>, <a href="#ref-31">31</a>]. Live attenuated vaccines, such as the serial passage-derived PMZ8 strain in ducks, offer improved immunogenicity [<a href="#ref-32">32</a>]. Gamma-irradiated whole-cell vaccines adjuvanted with Montanide or chitosan induce robust antibody and Th1/Th2 cytokine responses in chickens [<a href="#ref-31">31</a>, <a href="#ref-33">33</a>]. Subunit vaccines based on recombinant PlpE with flagellin as an adjuvant enhance T-cell-mediated immunity [<a href="#ref-25">25</a>]. Hydrogel-based inactivated vaccines provide sustained antigen release and improved protection in chickens [<a href="#ref-34">34</a>]. Truncated LPS outer core mutants are being explored as live, DIVA-compatible vaccine candidates for ducks [<a href="#ref-12">12</a>].
Biosecurity and Control
Effective control relies on strict biosecurity measures. All-in-all-out production, rodent and wild bird exclusion, proper sanitation of feed and water, and quarantine of new introductions are essential [<a href="#ref-2">2</a>, <a href="#ref-15">15</a>, <a href="#ref-16">16</a>]. Early detection and depopulation of affected flocks limit spread. Land cover management, such as reducing proximity to waterfowl habitats, can reduce outbreak risk [<a href="#ref-15">15</a>]. The "fowl cholera vaccine" is recommended in endemic areas, with booster doses administered according to local epidemiological data.
The term "avian coryn" may be confused with fowl cholera in field settings. It is important to perform laboratory differentiation, as infectious coryza responds to different antimicrobials and vaccines.
Mermaid Diagram: Diagnostic and Management Decision Tree for Suspected Fowl Cholera
flowchart TD
A["Suspected fowl cholera based on clinical signs and mortality"] --> B{"Perform necropsy and bacterial culture"}
B --> C["Gram-negative, bipolar staining rods isolated"]
C --> D{"Confirm by kmt1 PCR or LAMP"}
D --> E["Positive for P. multocida"]
E --> F["Antimicrobial susceptibility testing"]
F --> G{"Multidrug resistant?"}
G -->|"Yes"| H["Use targeted therapy based on MIC; consider probiotics or phytotherapeutics"]
G -->|"No"| I["Administer susceptible antibiotic"]
E --> J["Implement biosecurity and review vaccination protocol"]
J --> K["Vaccinate in-contact flocks with bacterin or live attenuated vaccine"]
K --> L["Monitor mortality and seroconversion"]
Antimicrobial Resistance
Antimicrobial resistance (AMR) in avian P. multocida is an escalating concern. Phenotypic resistance to tetracyclines, penicillins, and sulfonamides is common in isolates from poultry and rabbits [<a href="#ref-19">19</a>, <a href="#ref-20">20</a>, <a href="#ref-23">23</a>]. Genomic studies from Bangladesh, Ethiopia, China, and the USA reveal that MDR strains carry resistance genes on mobile genetic elements, facilitating horizontal spread [<a href="#ref-18">18</a>, <a href="#ref-20">20</a>, <a href="#ref-23">23</a>, <a href="#ref-27">27</a>]. Fluoroquinolone resistance is increasingly reported in some regions [<a href="#ref-19">19</a>, <a href="#ref-23">23</a>]. Surveillance programs integrating phenotypic and genomic AMR detection are recommended for guiding empirical therapy and preserving antimicrobial efficacy.
Genetic Diversity and Molecular Epidemiology
P. multocida populations in poultry exhibit considerable genetic diversity. Multilocus sequence typing (MLST) and capsular typing differentiate strains. ST20 is prevalent in Australian poultry [<a href="#ref-16">16</a>]. In Bangladesh, type B:2 strains have been isolated from fowl cholera outbreaks, a genotype more commonly associated with hemorrhagic septicemia in cattle [<a href="#ref-27">27</a>]. Phase variation in glycosyltransferase genes contributes to LPS diversity and may be linked to vaccine escape [<a href="#ref-9">9</a>]. Whole-genome sequencing of eight diverse isolates representing all LPS outer core loci has refined our understanding of LPS biosynthesis and its role in host adaptation [<a href="#ref-8">8</a>].
Specific Host Susceptibility
Native chicken breeds, such as the Nicobari from India, exhibit disease tolerance and enhanced immune responses following experimental P. multocida A:1 challenge compared to commercial broilers [<a href="#ref-35">35</a>]. This genetic resistance may involve differences in innate immune signaling and may inform future selective breeding and vaccine strategies [<a href="#ref-35">35</a>]. Embryonated chicken egg models are used to assess virulence of isolates, with death patterns correlating with field pathogenicity [<a href="#ref-21">21</a>].
Conclusion
Fowl cholera remains a major bacterial threat to poultry production worldwide. The disease is caused by Pasteurella multocida, a pathogen with a sophisticated arsenal of virulence factors including capsule, LPS, and PMT. Clinical presentation ranges from peracute death to chronic localized infections. Diagnosis relies on culture, molecular methods such as kmt1 PCR and LAMP, and genomic characterization. Management requires integrated strategies including targeted antimicrobial therapy based on susceptibility testing, vaccination with improved bacterins or subunit vaccines, and strict biosecurity. The emergence of MDR strains underscores the need for continued surveillance and development of alternative control measures such as probiotics and phytotherapeutics. Future research should focus on cross-protective vaccines, host resistance mechanisms, and the ecological drivers of outbreaks.